• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Target Insights >Immunoinformatics Approach in Designing Epitope-based Vaccine against Meningitis-inducing Bacteria (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae Type b)
【24h】

Immunoinformatics Approach in Designing Epitope-based Vaccine against Meningitis-inducing Bacteria (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae Type b)

机译：免疫信息学方法在设计针对针对脑膜炎的细菌（肺炎链球菌，脑膜炎奈瑟氏球菌和b型流感嗜血杆菌）的基于表位的疫苗设计中的应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Meningitis infection is one of the major threats during Hajj season in Mecca. Meningitis vaccines are available, but their uses are limited in some countries due to religious reasons. Furthermore, they only give protection to certain serogroups, not to all types of meningitis-inducing bacteria. Recently, research on epitope-based vaccines has been developed intensively. Such vaccines have potential advantages over conventional vaccines in that they are safer to use and well responded to the antibody. In this study, we developed epitope-based vaccine candidates against various meningitis-inducing bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b. The epitopes were selected from their protein of polysaccharide capsule. B-cell epitopes were predicted by using BCPred, while T-cell epitope for major histocompatibility complex (MHC) class I was predicted using PAProC, TAPPred, and Immune Epitope Database. Immune Epitope Database was also used to predict T-cell epitope for MHC class II. Population coverage and molecular docking simulation were predicted against previously generated epitope vaccine candidates. The best candidates for MHC class I- and class II-restricted T-cell epitopes were MQYGDKTTF, MKEQNTLEI, ECTEGEPDY, DLSIVVPIY, YPMAMMWRNASNRAI, TLQMTLLGIVPNLNK, ETSLHHIPGISNYFI, and SLLYILEKNAEMEFD, which showed 80% population coverage. The complexes of class I T-cell epitopes-HLA-C*03:03 and class II T-cell epitopes-HLA-DRB1*11:01 showed better affinity than standards as evaluated from their δGbinding value and the binding interaction between epitopes and HLA molecules. These peptide constructs may further be undergone in vitro and in vivo testings for the development of targeted vaccine against meningitis infection.
机译：脑膜炎感染是麦加朝j季期间的主要威胁之一。脑膜炎疫苗可用，但由于宗教原因在某些国家限制了其使用。此外，它们仅对某些血清群提供保护，而不对所有类型的诱发脑膜炎的细菌提供保护。最近，对基于表位的疫苗的研究得到了深入的发展。这种疫苗与常规疫苗相比具有潜在的优势，因为它们使用更安全并且对抗体反应良好。在这项研究中，我们开发了针对多种脑膜炎诱导细菌（包括肺炎链球菌，脑膜炎奈瑟氏球菌和b型流感嗜血杆菌）的基于抗原决定簇的候选疫苗。从它们的多糖荚膜蛋白中选择表位。使用BCPred可预测B细胞表位，而使用PAProC，TAPPred和免疫表位数据库可预测主要组织相容性复合物（MHC）I类的T细胞表位。免疫表位数据库也用于预测II类MHC的T细胞表位。针对先前产生的表位疫苗候选物，预测了种群覆盖率和分子对接模拟。 MHC I类和II类限制性T细胞表位的最佳候选者是MQYGDKTTF，MKEQNTLEI，ECTEGEPDY，DLSIVVPIY，YPMAMMWRNASNRAI，TLQMTLLGIVPNLNK，ETSLHHIPGISNYFI和SLLYILEKNAEMEFD，它们显示80％的人口覆盖率。从它们的δG结合值和抗原决定簇之间的结合相互作用评估，I类T细胞表位-HLA-C * 03：03和II类T细胞表位-HLA-DRB1 * 11：01的复合物表现出比标准品更好的亲和力。 HLA分子。可以进一步对这些肽构建体进行体外和体内测试，以开发针对脑膜炎感染的靶向疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号